Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190895 | 0.89 | BRD4 (0.45) | BRD4SPHK1 | |
| SCHEMBL21190867 | 0.83 | BRD4 (0.47) | BRD4 | |
| SCHEMBL21190902 | 0.82 | BRD4 (0.49) | BRD4SPHK1 | |
| SCHEMBL21190849 | 0.77 | BRD4 (0.44) | BRD4SPHK1 | |
| SCHEMBL16658429 | 0.75 | BRD4 (0.38) | BRD4 | |
| SCHEMBL21191141 | 0.74 | BRD4 (0.39) | BRD4 | |
| SCHEMBL21191045 | 0.74 | CSNK2A1 (0.39) | — | |
| SCHEMBL21190845 | 0.73 | BRD4 (0.43) | BRD4SPHK1 | |
| SCHEMBL20443248 | 0.72 | PTGS2 (0.46) | BRD4 | |
| SCHEMBL20157282 | 0.71 | LIPG (0.37) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885MCHR1 3908/4885SPHK1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.